Image-empty-state.png

Keren Haruvi

Director of the Board

Ms. Haruvi is the Head of M&A at Novartis International AG, advising the Board and senior management, executing mid-large M&A activities across the Group and member of the Finance Leadership team. From 2004 to October 2017, Ms. Haruvi served in various positions at Teva Pharmaceutical Industries including as Senior VP, Global Business Development and Alliance Management and Senior VP, Head of M&A and Transactions Analytics, evaluating and leading global M&A, divestitures and joint venture deals across the globe from scouting to closing and execution.

CONTACT US

Tel: +972 (0)77 335 2506

Fax: +972 (0)3 650 5594

office@taliazhealth.com

2 Prof. Yehezkel Kaufmann St.

(15th Floor), Tel Aviv-Yafo, Israel

  • LinkedIn
  • Twitter
  • Facebook
PREDICTIX_Logo_Dark.png

Disclaimer: Taliaz is developing the PREDICTIX Genetics and PREDICTIX Digital products. PREDICTIX (Genetics) Antidepressant is currently available for commercial use in the EU and Israel. Outside of the EU and Israel, PREDICTIX Genetics products are currently limited by law for investigational use only. PREDICTIX Digital products are currently limited by law for investigational use only. 

Copyright © 2020 PREDICTIX by TALIAZ Ltd. All Rights Reserved